With more than a dozen immunomodulatory disease-modifying therapies (DMTs) available to treat multiple sclerosis (MS) and more in the pipeline, the treatment journey for U.S. MS patients continues…
Pulmonary arterial hypertension (PAH) is a rare, life-threatening disorder characterized by high blood pressure in the arteries of the lungs. It is a progressive condition marked by considerable…
Disease stage, primary tumor resectability, and BRAF mutation status are key parameters influencing the treatment paradigm of malignant melanoma patients. BRAF/MEK inhibitor combination regimens,…
Attention-deficit-hyperactivity disorder (ADHD) is one of the most common childhood disorders that can continue into adulthood. For decades, childhood ADHD has been treated primarily with CNS…
Pulmonary arterial hypertension (PAH) is a rare, life-threatening disorder characterized by high blood pressure in the arteries of the lungs. It is a progressive condition marked by considerable…
Multiple myeloma remains an incurable hematological malignancy despite the availability of numerous treatment options. Resistance to therapy is the primary challenge associated with the disease’…
Diabetic nephropathy (DN), also referred to as diabetic kidney disease, is a common complication of diabetes. The DN drug market comprises a wide variety of antidiabetic and antihypertensive drugs…
Nonalcoholic steatohepatitis (NASH) has the potential to be a large and lucrative therapy market owing to the prevalence of the disease and the lack of approved agents. Patients with NASH are at…
Clarivate Epidemiology’s coverage of idiopathic pulmonary fibrosis (IPF) comprises epidemiological estimates of key patient populations in the Asia-Pacific region (Australia, Hong Kong, Indonesia…
Clarivate Epidemiology’s coverage of idiopathic pulmonary fibrosis (IPF) comprises epidemiological estimates of key patient populations in the Middle East and Africa (Egypt, Nigeria, Saudi Arabia…
Diabetic nephropathy (DN), also referred to as diabetic kidney disease, is a common complication of diabetes. The DN drug market comprises a wide variety of antidiabetic and antihypertensive drugs…
Clarivate’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts of key idiopathic pulmonary fibrosis (IPF) patient populations covering 171…
Clarivate Epidemiology’s coverage of idiopathic pulmonary fibrosis (IPF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of IPF…
Clarivate Epidemiology’s coverage of idiopathic pulmonary fibrosis (IPF) comprises epidemiological estimates of key patient populations in the emerging pharmaceutical markets (China, India,…
Clarivate Epidemiology’s coverage of idiopathic pulmonary fibrosis (IPF) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United…
